Filgrastim biosimilar - Phage Pharmaceuticals
Latest Information Update: 03 Aug 2015
At a glance
- Originator Phage Pharmaceuticals
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
- Mechanism of Action Granulocyte colony stimulating factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 05 Jun 2015 No development reported - Preclinical for Neutropenia in USA (SC)